We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

1910:HKEXSamsonite Group S.A. Analysis

Data as of 2026-07-28 - not real-time

HK$13.82

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Samsonite is trading at HK$13.82, barely above the computed support of HK$13.04 and well below the 20‑day SMA of HK$13.70. The 20‑day SMA sits under the 50‑day SMA (HK$14.01) and both are under the 200‑day SMA (HK$16.85), confirming a bearish alignment on the longer term. Nevertheless, the MACD histogram is positive and the MACD signal is flagged “bullish”, suggesting short‑term momentum could be turning higher. The RSI of 50.3 points to a neutral market stance without clear over‑bought or over‑sold pressure. Volume has remained stable but is modest relative to the 10‑day and 3‑month averages, indicating limited short‑term liquidity.
On the valuation side, the stock trades at a forward PE of about 8.7 and a price‑to‑book of 1.5, both well below industry averages, reinforcing a value‑oriented profile. The dividend yield of 5.71% and a payout ratio near 52% are supported by solid operating cash flow of HK$0.58 bn and free cash flow of HK$0.43 bn, making the dividend appear sustainable. However, the DCF‑derived fair value of roughly HK$3.6 is far lower than the current price, flagging the equity as potentially overvalued relative to intrinsic estimates. Analysts are overwhelmingly positive, with a “strong buy” consensus and a median target of HK$20.06, implying roughly 44% upside from today’s price. The company’s ROE of 18% and gross margin of 59.5% demonstrate operational strength, while revenue is growing modestly at 4.1% YoY. A high debt‑to‑equity ratio of 138% raises leverage concerns, but the balance sheet is cushioned by HK$0.67 bn of cash and a healthy debt service capacity.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with bearish SMA hierarchy
  • Positive MACD histogram indicating potential short‑term bounce
  • Stable but modest trading volume limiting immediate upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong dividend yield and sustainable payout
  • Analyst consensus strong buy with ~44% upside target
  • Solid ROE and margins supporting earnings growth

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage (debt‑to‑equity >130%) requiring monitoring
  • Diversified brand portfolio and global exposure mitigating single‑market risk
  • Value‑oriented valuation metrics offset by DCF undervaluation concerns

Key Metrics & Analysis

Financial Health

Revenue Growth4.10%
Profit Margin7.73%
P/E Ratio8.5
ROE18.07%
ROA6.42%
Debt/Equity138.54
P/B Ratio1.5
Op. Cash FlowHK$583.2M
Free Cash FlowHK$428.8M

Technical Analysis

TrendBearish
RSI50.3
SupportHK$13.04
ResistanceHK$14.20
MA 20HK$13.70
MA 50HK$14.01
MA 200HK$16.85
MACDBullish
VolumeStable
Fear & Greed Index87.34

Valuation

Fair ValueHK$3.56
Target PriceHK$20.00
Upside/Downside44.72%
GradeOvervalued
TypeValue
Dividend Yield5.71%

Risk Assessment

Beta0.57
Volatility25.03%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.